Organon
Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
DitchCarbon Score
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon's score of 43 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organon's reported carbon emissions
In 2023, Organon reported total carbon emissions of approximately 7,000,000 kg CO2e, comprising 2,272,000 kg CO2e from Scope 1 and 5,557,000 kg CO2e from Scope 2 emissions. The company also disclosed Scope 3 emissions, which included 415,000 kg CO2e from business travel, 830,000 kg CO2e from employee commuting, 130,000 kg CO2e from waste generated in operations, and 1,840,000 kg CO2e from transportation and distribution activities (920,000 kg CO2e upstream and downstream each). Organon has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by more than 25% from 2020 levels by 2025. This commitment reflects the company's proactive approach to addressing climate change and aligns with industry standards for emissions reduction. In 2022, the company reported total emissions of approximately 6,000,000 kg CO2e, with Scope 1 emissions at 1,122,000 kg CO2e and Scope 2 emissions at 5,677,000 kg CO2e. The Scope 3 emissions for that year were significantly higher, indicating areas for improvement in their supply chain and operational practices. Organon's emissions data is not cascaded from any parent company, ensuring that their commitments and performance are independently reported. The company continues to focus on enhancing its sustainability practices and reducing its carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organon is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
